search
Back to results

Evaluation of a High Protein, High Calorie Pudding in Adults With/or at Risk for Malnutrition

Primary Purpose

Gastrointestinal Tolerance

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Experimental Nutritional Pudding
Sponsored by
Abbott Nutrition
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Gastrointestinal Tolerance

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject has voluntarily signed and dated an ICF approved by an IEC, and provided applicable privacy authorization prior to any participation
  • Subject is considered by a dietitian or clinician as malnourished or at risk for malnutrition based on current use of an oral nutritional supplement (ONS), recently identified as malnourished or at risk of malnutrition based on validated malnutrition screening tool or has had weight loss within last two months as a result of a hospitalization or chronic illness
  • Subject currently has normal GI function
  • Subject requires ONS and is willing to comply with the study protocol

Exclusion Criteria:

  • Subject has severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder affecting abilities to answer questions, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures
  • Subject had a history of diabetes as evidenced by taking antihyperglycemic medications or by self-reported dietary modification
  • Subject is currently taking or has taken antibiotics within 1 week prior to enrollment
  • Subject has undergone major GI surgery less than 3 months prior to enrollment in the study
  • Subject has current active malignant disease or was treated within the last 6 months for cancer, except basal or squamous cell skin carcinoma, prior to enrollment
  • Subject has an immunodeficiency disorder
  • Subject has had a myocardial infarction within the last 3 months prior to enrollment
  • Subject is known to be allergic or intolerant to any ingredient found in the study product
  • Subject has an aversion to any of the flavours of product being tested
  • Subject has an obstruction of the GI tract precluding ingestion or absorption of the study product, inflammatory bowel disease, gastric esophageal reflux disease, short bowel syndrome, or other major gastrointestinal disease-causing symptoms including (but not limited to) uncontrollable severe diarrhea, nausea, or vomiting
  • Subject is currently taking medications/dietary supplements/substances that could profoundly modulate metabolism or affect gastrointestinal motility
  • Participation in another study that has not been approved as a concomitant study
  • Subject has a clinical condition that is contraindicated with this product as determined by the clinician in accordance with standard of care
  • Subject is pregnant

Sites / Locations

  • North Coast Medical Ltd, Newquay Health Centre
  • The Alverton Practice, Atlantic Medical
  • Morrab Surgery

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Experimental Nutritional Pudding

Arm Description

2 servings per day

Outcomes

Primary Outcome Measures

Gastro-Intestinal Tolerance
Subject completed Bristol Stool Type questionnaire; Stool is classified into 7 groups (Types 1-7) with Type 3-4 as ideal stools

Secondary Outcome Measures

Nutritional Supplement Palatability
Subject completed questionnaire; 4 questions scaled from 1 -Dislike Extremely to 9-Like Extremely; 2 questions scaled from Not at all Enough to Far Too
Nutritional Supplement Compliance
Subject completed daily intake questionnaire including amount of serving consumed

Full Information

First Posted
June 7, 2021
Last Updated
January 12, 2022
Sponsor
Abbott Nutrition
search

1. Study Identification

Unique Protocol Identification Number
NCT04945083
Brief Title
Evaluation of a High Protein, High Calorie Pudding in Adults With/or at Risk for Malnutrition
Official Title
Gastrointestinal Tolerance and Acceptability of a High Protein, High Calorie Pudding in Adult Patients With/or at Risk for Malnutrition
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
January 13, 2021 (Actual)
Primary Completion Date
December 9, 2021 (Actual)
Study Completion Date
December 9, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Nutrition

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a multi-center, prospective, non-randomized, non-blinded, single-arm, single treatment study to evaluate the tolerance of a nutritional pudding.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Tolerance

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental Nutritional Pudding
Arm Type
Experimental
Arm Description
2 servings per day
Intervention Type
Other
Intervention Name(s)
Experimental Nutritional Pudding
Intervention Description
High Calorie, High Protein pudding
Primary Outcome Measure Information:
Title
Gastro-Intestinal Tolerance
Description
Subject completed Bristol Stool Type questionnaire; Stool is classified into 7 groups (Types 1-7) with Type 3-4 as ideal stools
Time Frame
Study Day 1 to Study Day 8
Secondary Outcome Measure Information:
Title
Nutritional Supplement Palatability
Description
Subject completed questionnaire; 4 questions scaled from 1 -Dislike Extremely to 9-Like Extremely; 2 questions scaled from Not at all Enough to Far Too
Time Frame
Study Day 1 to Study Day 8
Title
Nutritional Supplement Compliance
Description
Subject completed daily intake questionnaire including amount of serving consumed
Time Frame
Study Day 1 to Study Day 28
Other Pre-specified Outcome Measures:
Title
Weight
Description
For BMI Calculation
Time Frame
Baseline to Study Day 28
Title
Height
Description
For BMI Calculation
Time Frame
Baseline to Study Day 28
Title
Medication Usage
Description
Subject reported medication usage
Time Frame
Baseline to Study Day 28
Title
Adverse Events
Description
Subject reported adverse events
Time Frame
Baseline to Study Day 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject has voluntarily signed and dated an ICF approved by an IEC, and provided applicable privacy authorization prior to any participation Subject is considered by a dietitian or clinician as malnourished or at risk for malnutrition based on current use of an oral nutritional supplement (ONS), recently identified as malnourished or at risk of malnutrition based on validated malnutrition screening tool or has had weight loss within last two months as a result of a hospitalization or chronic illness Subject currently has normal GI function Subject requires ONS and is willing to comply with the study protocol Exclusion Criteria: Subject has severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder affecting abilities to answer questions, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures Subject had a history of diabetes as evidenced by taking antihyperglycemic medications or by self-reported dietary modification Subject is currently taking or has taken antibiotics within 1 week prior to enrollment Subject has undergone major GI surgery less than 3 months prior to enrollment in the study Subject has current active malignant disease or was treated within the last 6 months for cancer, except basal or squamous cell skin carcinoma, prior to enrollment Subject has an immunodeficiency disorder Subject has had a myocardial infarction within the last 3 months prior to enrollment Subject is known to be allergic or intolerant to any ingredient found in the study product Subject has an aversion to any of the flavours of product being tested Subject has an obstruction of the GI tract precluding ingestion or absorption of the study product, inflammatory bowel disease, gastric esophageal reflux disease, short bowel syndrome, or other major gastrointestinal disease-causing symptoms including (but not limited to) uncontrollable severe diarrhea, nausea, or vomiting Subject is currently taking medications/dietary supplements/substances that could profoundly modulate metabolism or affect gastrointestinal motility Participation in another study that has not been approved as a concomitant study Subject has a clinical condition that is contraindicated with this product as determined by the clinician in accordance with standard of care Subject is pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Camprubi, PhD
Organizational Affiliation
Abbott Nutrition
Official's Role
Study Chair
Facility Information:
Facility Name
North Coast Medical Ltd, Newquay Health Centre
City
Newquay
State/Province
Cornwall
ZIP/Postal Code
TR7 1RU
Country
United Kingdom
Facility Name
The Alverton Practice, Atlantic Medical
City
Penzance
State/Province
Cornwall
ZIP/Postal Code
TR18 3DX
Country
United Kingdom
Facility Name
Morrab Surgery
City
Penzance
State/Province
Cornwall
ZIP/Postal Code
TR18 4EL
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of a High Protein, High Calorie Pudding in Adults With/or at Risk for Malnutrition

We'll reach out to this number within 24 hrs